A US Food and Drug Administration panel narrowly voted in favour of emergency use authorization of an antiviral pill from Merck and Ridgeback Biotherapeutics.
- the drug is called molnupiravir
- the pill would be sued to treat COVID-19
- taken twice a day for five days
- It was a tight vote, 13 to 10
The FDA isn't obligated to follow the recommendations of its advisers but it usually does.